A mathematical simulation of the inflammatory response to anthrax infection

Shock

Volumn 29, Issue 1, 2008, Pages 104-111

  Kumar, Rukmini ^a   Chow, Carson C ^a   Bartels, John D ^b   Clermont, Gilles ^c   Vodovotz, Yoram ^d  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b IMMUNETRICS INC   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Anthrax; Biowarfare; Mathematical model; Sepsis; Simulation; Vaccine

Indexed keywords

ANTHRAX VACCINE; ANTIBIOTIC AGENT; ANTIBODY; BACTERIAL ANTIGEN;

ANTHRAX; ANTIBIOTIC THERAPY; ARTICLE; INFLAMMATION; MATHEMATICAL MODEL; SHOCK; SIMULATION; SURVIVAL; VACCINATION;

EID: 37549004342     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Abramova FA, Grinberg LM, Yampolskaya OV, Walker DH: Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc Natl Acad Sci U S A 90:2291-2294, 1993.
2. Read TD, Salzberg SL, Pop M, Shumway M, Umayam L, Jiang L, Holtzapple E, Busch JD, Smith KL, Schupp JM, et al.: Comparative genome sequencing for discovery of novel polymorphisms in Bacillus anthracis. Science 296:2028-2033, 2002.
3. An G: Agent-based computer simulation and sirs: building a bridge between basic science and clinical trials. Shock 16:266-273, 2001.
4. Dhawan B, Desikan-Trivedi P, Chaudhry R, Narang P: Bioterrorism: a threat for which we are ill prepared. Natl Med J India 14:225-230, 2001.
5. Shafazand S, Doyle R, Ruoss S, Weinacker A, Raffin TA: Inhalational anthrax: epidemiology, diagnosis, and management. Chest 116:1369-1376, 1999.
6. Meselson M, Guillemin J, Hugh-Jones M, Langmuir A, Popova I, Shelokov A, Yampolskaya O: The Sverdlovsk anthrax outbreak of 1979. Science 266:1202-1208, 1994.
7. Hanna P: Anthrax pathogenesis and host response. 225:13-35, 1998.
8. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 348:138-150, 2003.
9. Nass M: Anthrax vaccine. Model of a response to the biologic warfare threat. Infect Dis Clin North Am 13:187-208, viii, 1999.
10. Little SF: Anthrax vaccines: a development update. BioDrugs 19:233-245, 2005.
11. Brey RN: Molecular basis for improved anthrax vaccines. Adv Drug Deliv Rev 57:1266-1292, 2005.
12. Fellows PF, Linscott MK, Ivins BE, Pitt ML, Rossi CA, Gibbs PH, Friedlander AM: Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine 19:3241-3247, 2001.
13. Clermont G, Bartels J, Kumar R, Constantine G, Vodovotz Y, Chow C: In silico design of clinical trials: a method coming of age. Crit Care Med 32:2061-2070, 2004.
14. Chow CC, Clermont G, Kumar R, Lagoa C, Tawadrous Z, Gallo D, Betten B, Bartels J, Constantine G, Fink MP, et al.: The acute inflammatory response in diverse shock states. Shock 24:74-84, 2005.
15. Janeway CA Jr, Medzhitov R: Innate immune recognition. Annu Rev Immunol 20:197-216, 2002.
16. Jaeschke H, Smith CW: Mechanisms of neutrophil-induced parenchymal cell injury. J Leukoc Biol 61:647-653, 1997.
17. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31:1250-1256, 2003.
18. Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E: Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest 103:565-575, 1993.
19. Read TD, Salzberg SL, Pop M, Shumway M, Umayam L, Jiang L, Holtzapple E, Busch JD, Smith KL, Schupp JM, et al.: Comparative genome sequencing for discovery of novel polymorphisms in Bacillus anthracis. Science 296:2028-2033, 2002.
20. Abramova FA, Grinberg LM, Yampolskaya OV, Walker DH: Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc Natl Acad Sci U S A 90:2291-2294, 1993.
21. Dai Z, Koehler TM: Regulation of anthrax toxin activator gene (atxA) expression in Bacillus anthracis: temperature, not CO2/bicarbonate, affects AtxA synthesis. Infect Immun 65:2576-2582, 1997.
22. O'Brien J, Friedlander A, Dreier T, Ezzell J, Leppla S: Effects of anthrax toxin components on human neutrophils. Infect Immun 47:306-310, 1985.
23. Bonventre JV: Molecular response to cytotoxic injury: role of inflammation, MAP kinases, and endoplasmic reticulum stress response. Semin Nephrol 23:439-448, 2003.
24. Kumar S, Boehm J, Lee JC: p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2:717-726, 2003.
25. Friedlander AM: Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process. J Biol Chem 261:7123-7126, 1986.
26. Hanna PC, Acosta D, Collier RJ: On the role of macrophages in anthrax. Proc Natl Acad Sci U S A 90:10198-10201, 1993.
27. Brossier F, Weber-Levy M, Mock M, Sirard JC: Protective antigen-mediated antibody response against a heterologous protein produced in vivo by Bacillus anthracis. Infect Immun 68:5731-5734, 2000.
28. Pezard C, Weber M, Sirard JC, Berche P, Mock M: Protective immunity induced by Bacillus anthracis toxin-deficient strains. Infect Immun 63:1369-1372, 1995.
29. Clermont G, Chow CC, Constantine GM, Vodovotz Y, Bartels J: Mathematical and statistical modeling of acute inflammation. In Classification, Clustering, and Data Mining Applications. Proceedings of the IFCS. New York: Springer, pp 457-467, 2004.
30. Chow CC, Clermont G, Kumar R, Lagoa C, Tawadrous Z, Gallo D, Betten B, Bartels J, Constantine G, Fink MP, et al.: The acute inflammatory response in diverse shock states. Shock 24:74-84, 2005.
31. Dixon TC, Meselson M, Guillemin J, Hanna PC: Anthrax. N Engl J Med 341:815-826, 1999.
32. Kalns J, Morris J, Eggers J, Kiel J: Delayed treatment with doxycycline has limited effect on anthrax infection in BLK57/B6 mice. Biochem Biophys Res Commun 297:506-509, 2002.
33. Friedlander AM, Welkos SL, Ivins BE: Anthrax vaccines. Curr Top Microbiol Immunol 271:33-60, 2002.
34. Greenfield RA, Bronze MS: Prevention and treatment of bacterial diseases caused by bacterial bioterrorism threat agents. Drug Discov Today 8:881-888, 2003.
35. Leppla SH, Robbins JB, Schneerson R, Shiloach J: Development of an improved vaccine for anthrax. J Clin Invest 110:141-144, 2002.
36. Lemeshow S, Hosmer DW Jr: A review of goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiol 115:92-106, 1982.
37. Hanley JA: Receiver operating characteristic (ROC) methodology: the state of the art. Crit Rev Diagn Imaging 29:307-335, 1989.
38. Kumar R, Clermont G, Vodovotz Y, Chow CC: The dynamics of acute inflammation. J Theor Biol 230:145-155, 2004.
39. Reynolds A, Rubin J, Clermont G, Day J, Vodovotz Y, Ermentrout GB: A reduced mathematical model of the acute inflammatory response: I. Derivation of model and analysis of anti-inflammation. J Theor Biol 242:220-236, 2006.
40. Day J, Rubin J, Vodovotz Y, Chow CC, Reynolds A, Clermont G: A reduced mathematical model of the acute inflammatory response: II. Capturing scenarios of repeated endotoxin administration. J Theor Biol 242:237-256, 2006.
41. An G: Agent-based computer simulation and sirs: building a bridge between basic science and clinical trials. Shock 16:266-273, 2001.
42. Kumar R, Clermont G, Vodovotz Y, Chow CC: The dynamics of acute inflammation. J Theor Biol 230:145-155, 2004.
43. O'Brien J, Friedlander A, Dreier T, Ezzell J, Leppla S: Effects of anthrax toxin components on human neutrophils. Infect Immun 47:306-310, 1985.
44. Kudoh S, Suzuki K, Yamada M, Liu Q, Nakaji S, Sugawara K: Contribution of nitric oxide synthase to human neutrophil chemiluminescence. Luminescence 14:335-339, 1999.
45. Pacelli R, Wink DA, Cook JA, Krishna MC, DeGraff W, Friedman N, Tsokos M, Samuni A, Mitchell JB: Nitric oxide potentiates hydrogen peroxide-induced killing of Escherichia coli. J Exp Med 182:1469-1479, 1995.
46. McAllister RD, Singh Y, du Bois WD, Potter M, Boehm T, Meeker ND, Fillmore PD, Anderson LM, Poynter ME, Teuscher C: Susceptibility to anthrax lethal toxin is controlled by three linked quantitative trait loci. Am J Pathol 163:1735-1741, 2003.
47. Moayeri M, Haines D, Young HA, Leppla SH: Bacillus anthracis lethal toxin induces TNF-alpha-independent hypoxia-mediated toxicity in mice. J Clin Invest 112:670-682, 2003.
48. Cobb JP, Hotchkiss RS, Swanson PE, Chang K, Qiu Y, Laubach VE, Karl IE, Buchman TG: Inducible nitric oxide synthase (iNOS) gene deficiency increases the mortality of sepsis in mice. Surgery 126:438-442, 1999.
49. Nathan CF, Hibbs JB Jr: Role of nitric oxide synthesis in macrophage antimicrobial activity. Curr Opin Immunol 3:65-70, 1991.
50. Moayeri M, Martinez NW, Wiggins J, Young HA, Leppla SH: Mouse susceptibility to anthrax lethal toxin is influenced by genetic factors in addition to those controlling macrophage sensitivity. Infect Immun 72:4439-4447, 2004.
51. Raines KW, Kang TJ, Hibbs S, Cao GL, Weaver J, Tsai P, Baillie L, Cross AS, Rosen GM: Importance of nitric oxide synthase in the control of infection by Bacillus anthracis. Infect Immun 74:2268-2276, 2006.
52. Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Friedlander AM, Hauer J, McDade J, Osterholm MT, O'Toole T, et al.: Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 281:1735-1745, 1999.
53. Meselson M, Guillemin J, Hugh-Jones M, Langmuir A, Popova I, Shelokov A, Yampolskaya O: The Sverdlovsk anthrax outbreak of 1979. Science 266:1202-1208, 1994.
54. Vietri NJ, Purcell BK, Lawler JV, Leffel EK, Rico P, Gamble CS, Twenhafel NA, Ivins BE, Heine HS, Sheeler R, et al.: Short-course postexposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthrax. Proc Natl Acad Sci U S A 103:7813-7816, 2006.
55. Moayeri M, Martinez NW, Wiggins J, Young HA, Leppla SH: Mouse susceptibility to anthrax lethal toxin is influenced by genetic factors in addition to those controlling macrophage sensitivity. Infect Immun 72:4439-4447, 2004.
56. Raines KW, Kang TJ, Hibbs S, Cao GL, Weaver J, Tsai P, Baillie L, Cross AS, Rosen GM: Importance of nitric oxide synthase in the control of infection by Bacillus anthracis. Infect Immun 74:2268-2276, 2006.
57. Kalns J, Scruggs J, Millenbaugh N, Vivekananda J, Shealy D, Eggers J, Kiel J: TNF receptor 1, IL-1 receptor, and iNOS genetic knockout mice are not protected from anthrax infection. Biochem Biophys Res Commun 292:41-44, 2002.
58. Moayeri M, Haines D, Young HA, Leppla SH: Bacillus anthracis lethal toxin induces TNF-alpha-independent hypoxia-mediated toxicity in mice. J Clin Invest 112:670-682, 2003.
59. Prince JM, Levy RM, Bartels J, Baratt A, Kane JM 3rd, Lagoa C, Rubin J, Day J, Wei J, Fink MP, et al.: In silico and in vivo approach to elucidate the inflammatory complexity of CD14-deficient mice. Mol Med 12:88-96, 2006.